Popular insulin meets target in real-world studyNovo Nordisk’s DEVOTE study reveals interesting findings.
Diabetes drug Tresiba to make billionsTresiba, the long-acting insulin that just came on the market in January, stands to net Novo Nordisk billions of dollars.
Pricing report blasts asthma drug costIn the latest controversy over drug pricing, an organization said that the price of GlaxoSmithKline’s Nucala (mepolizumab), an injectable indicated for severe asthma patients with eosinophilic inflammation, is far over-priced.
First 2-drug combo for advanced melanoma, plus 5 more FDA actionsFirst 2-drug therapy approved for advanced melanoma and four other recent approvals by FDA relating to new drugs and treatments.
FDA approves long-acting insulin drugsFDA approved Tresiba (insulin degludec injection, Novo Nordisk) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection, Novo Nordisk) for the treatment of diabetes mellitus.
New insulin drug to enter crowded marketNovo Nordisk is expected to find out in October whether FDA will approve its long-acting insulin Tresiba for sale in the US market. However, if approved, Tresiba faces growing competition from Sanofi, which markets the leading basal insulin Lantus along with Toujeo.